Fosun Pharma has announced that the company and its controlling shareholder, Fosun International Limited, have submitted a joint application to the Stock Exchange of Hong Kong (SEHK) pursuant to Practice Note 15, seeking approval for the proposed spin-off listing. The SEHK has confirmed that Fosun Pharma and Fosun International may proceed with the proposed spin-off.
On June 26, 2026, the subsidiary, Fosun Antigen, submitted a listing application to the SEHK via its joint sponsors. The application seeks the listing of, and permission to deal in, Fosun Antigen's H shares on the Main Board of the SEHK.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments